Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Shares Rise on Data Presentation

NEW YORK (GenomeWeb News) – Shares of Accelr8 Technology rose 51 percent in Thursday afternoon trade after the firm issued a release saying it had presented results on its rapid tests for identifying multi-resistant organisms at the recent 109th General Meeting of the American Society for Microbiology.

Accelr8 said that it reported results for its rapid test for identifying organisms that produce the new KPC antibiotic-destroying enzyme. "KPC is the first rapidly spreading resistance enzyme to emerge that attacks all members of the largest and most important antibiotic super-family," Accelr8 said in a statement.

The Denver-based firm did not provide further details from the study.

It also said that it reported additional results from a collaborative study with the Denver Health Medical Center on new tests for two additional multi-drug resistant bacteria, Pseudomonas aeruginosa and Acinetobacter baumannii. Accelr8 said that researchers using its BACcel prototypes in three different labs yielded accurate results in less than three hours as compared to the two to three days required for standard culturing tests.

Acceler8 also noted that it had received a new US patent covering its OptiChem technology for hydroxyl functional coatings.

In late Thursday trade on the New York Stock Exchange, shares of Accelr8 were up $1.07 at $3.16.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.